Emerald Clinics share price soars 30% on new record

The Emerald Clinics share price has surged nearly 30% in early trade following an expansion announcement from the company today.

| More on:
cannabis leaves on a rising line graph representing growth of ASX cannabis share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in Emerald Clinics Ltd (ASX: EMD) have surged nearly 30% in early trade following an announcement from the company. At the time of writing, the Emerald Clinics share price had risen 29.5% to currently trade at 7.9 cents.

What did Emerald Clinics announce?

Earlier today, Emerald Clinics released an announcement which highlighted record appointments in Australia, plans for international expansion and a proposed name change.

Despite the restrictions induced by COVID-19, Emerald Clinics reported a record 795 appointments in July. The company noted continued month-on-month growth in comparison to subdued demand in the majority of health services.

As a result, Emerald Clinics informed investors that the company is actively hiring clinicians in order to meet growing demand for its services. In addition, the company is expanding its remote monitoring capabilities and increasing its data insight platforms.

Emerald Clinics also announced that the company intends to change its name to Emyria Limited. According to the company, the proposed name change is consistent with its global ambitions and rebranding, the latter of which better communicates its scope of practice. The planned name change follows the company's data collaboration with a United Kingdom partner. 

What does Emerald Clinics do?

Emerald Clinics is network of specialist and referral only medical clinics. The company's clinicians are trained specialists in the application of unregistered medicines, which include cannabinoid products.

The company also focuses on collecting and developing high quality, real-world evidence (RWE) data. Emerald's RWE data platform aims to improve patient care, identify novel uses for existing therapies and explore the performance of certain medicines.

As a result, the data insights from Emerald's RWE platforms can also be provided to pharmaceutical companies on a subscription payment model.

Emerald Clinics recently signed with Spectrum Biomedical, a UK-based subsidiary of the world's largest cannabis company Canopy Growth Corp. Under the agreement, Emerald will design and deliver RWE focused on the safety and clinical outcomes of cannabis-based medicines produced by Spectrum. 

Foolish takeaway

At the time of writing, the Emerald Clinics share price is trading nearly 30% higher at 7.9 cents. Shares in the company were up nearly 40% earlier today after hitting an intra-day high of 8.5 cents.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »

Three businesspeople leap high with the CBD in the background.
Share Market News

Boom! ASX 200 blasts to new record highs

ASX 200 investors just sent the benchmark index into uncharted territory.

Read more »